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This minireview touches upon the challenges and opportunities peptides experience on the
track to become an approved pharmaceutical.
Peptide attributes originally considered troublesome with respect to drug development
may now turn out to be more convenient rather than unfavourable.
Besides characteristic high target afﬁnity, biological peptides often exhibit higher than
expected stability. Clearly natural selective pressure has optimised these biomolecules
beyond what can be anticipated solely on the basis of their chemical nature. This conceptDrug development is gradually ﬁnding its way into the pharma and biotech industry, as illustrated by a rise in
medicinal peptide patent applications and developmental work.
© 2014 The Authors. Published by Elsevier B.V. on behalf of European Proteomics
Association (EuPA). This is an open access article under the CC BY-NC-SA license
major interest in their usage both as diagnostics as well as
therapeutics. In particular, modern-day analytical methods,1. Introduction
Drug development pipelines, which in the ﬁrst century of
the industry have been dominated by small molecules, are
characterised by high attrition rates. The road to market
authorisation has many obstacles and next to efﬁcacy and
tolerability, new drug candidates have to meet several other
requirements. Besides essential pharmacodynamics, pharma-
cokinetics, toxicity, and safety issues, also economic factors
are vital, including producibility, market competition, intel-
lectual property, and others. This is why in a typical drug
∗ Corresponding author at: Laboratory for Analytical Biotechnology &
University of Technology, Delft, Netherlands. Tel.: +31 15 278 2332.
E-mail address: p.d.e.m.verhaert@tudelft.nl (P. Verhaert).
http://dx.doi.org/10.1016/j.euprot.2014.05.003
2212-9685/© 2014 The Authors. Published by Elsevier B.V. on behalf of
article under the CC BY-NC-SA license (http://creativecommons.org/lic(http://creativecommons.org/licenses/by-nc-sa/3.0/).
development process of today, >90%novel drug candidates fail
between their identiﬁcation and being put on the market.
As peptides are readily degraded inside the human body,
which is equipped with roughly 600 molecularly different pro-
teases [37], this class of (bio)chemicals has long been held
ineligible for drug development, and deemed widely inferior
to small molecules. Despite such neglect, a number of recent
technological breakthroughs and advances have sparkedInnovative Peptide Biology, Department of Biotechnology, Delft
which greatly excel in sensitivity, resolution and through-
put over those available to the traditional pharmaceutical
European Proteomics Association (EuPA). This is an open access
enses/by-nc-sa/3.0/).
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ndustry, facilitate the discovery and identiﬁcation of a wealth
f novel peptides with pharmaceutical potential. Further-
ore, present combinatorial chemistry provides the means
o modify them and to create completely artiﬁcial variants
nd alternatives. Some pharmacodynamic ‘weaknesses’ of
eptides cannot be fully abolished this way, but clever formu-
ations may mask or amend them. In combination with an
n-depth study of the complete biology of peptides in their
riginal natural sources, current (bio)technologies have the
otential to generate an ample spectrum of efﬁcacious and
afe peptide drugs.
Here, we review the steady rise of therapeutic peptides
hich is apparent in the pharmaceutical and biotech indus-
ry of today. We will focus on how a peptide drug candidate
asses the various phases in the traditional pharmaceutical
evelopment pipeline and the differences herein to both small
olecules and the larger biopharmaceuticals. With this, we
im to reveal that peptides are by far not ‘undrugable’, but,
nstead, offer immense medicinal potential.
. Concept/history
n terms of chemical complexity, peptides ﬁll a niche between
ypical small molecule chemicals and the larger proteins. Just
s the latter, they feature a modular structure with amino
cids linked by peptide bonds as base units. Their size is
imited, with arbitrary boundaries set at up to 100 residues
20]. Nonetheless, within these limits, peptides exhibit mul-
ifarious structures with regard to amino acid sequence,
ost-translational modiﬁcations and resultant spatial shape.
Starting about a century ago (World War I), the advent
f the modern drug era came with pioneering therapeutic
ompounds like the opiate morphine and the cyclic peptide
enicillin, followed in the early 1920s by the (poly)peptide
nsulin. These drugs introduced a new standard in disease
reatment. Although peptides thus held their place among
he initial therapeutic discoveries [50], smallmolecules rapidly
ook preference in the drug development industry, primarily
ue to their ease of production, simplicity of administra-
ion (as oral ‘pill’) and superior pharmacodynamic properties.
eanwhile, the rapid enzymatic breakdown of peptides in
iological systems and the consequently more challenging
dministration routes (e.g. injection such as for insulin) led
o more and more neglect of this biochemical class in the
raditional drug development process.
In the 21st century, the pharmaceutical business is expe-
iencing dramatic changes. Stringent safety regulations,
engthy compound development processes and massive
nancial efforts (Vlieghe, Lisowski et al., 2010) all incur con-
ern that, despite the increasing investment into research and
evelopment, medicinal innovation is declining. Especially
he last decade has seen a major paradigm shift in the scope
f the pharmaceutical sector, focusing more on orphan or
epurposed drugs and reducing production costs, as to endure
he high expenses associated with drug development. Fewer
ew drugs make it to the market and the patent protection
f current blockbuster drugs is deteriorating, with a result-
ng drainage of the drug pipelines. All this may ultimately
ush the pharmaceutical industry towards a new frontier in4 ( 2 0 1 4 ) 58–69 59
modern drug development. Fresh strategies are needed to
revive pharma’s lost momentum and we agree with Vlieghe
and coauthors (Vlieghe, Lisowski et al., 2010) that the sector’s
hope (partly) lies in peptides.
3. Peptide discovery
3.1. Natural sources
Nature harbours an impressive variety of biologically active
peptides expressed invirtually all living species and, therefore,
represents one of the most promising sources for peptide drug
discovery (see also www.NP2D.com).
Within the multicellular body, peptides exert diverse
biological roles, most prominently as signalling/regulatory
molecules in a broad variety of physiological processes,
including defence, immunity, stress, growth, homeostasis,
and reproduction [24].
Through evolution, numerous peptides have evolved to
exhibit their ‘natural’ bioactivity outside of the producing
organism. Many of these have been isolated and characterised
from the skin of frogs and toads [49,55]. These genetically
encoded compounds have been shown to protect and defend
their manufacturers against many foes, both predators and
pathogens [13]. Hitherto, over 300 antimicrobial peptides have
been identiﬁed from amphibians that hold promise for future
antibiotic research and development [33].
Intriguingly, many externally active peptides have evolved
as means of active predation, especially in venomous animals
such as spiders, snails and snakes (see [64]). While the toxicity
arises from interfering with neuronal transmission (blocking
synaptic signalling, ion channel; e.g. conotoxins) or, in general,
disrupting critical biochemical signalling networks within the
prey’s body [61], lowdoses of these peptides can actually coun-
teract disturbances from diverse disorders. Accordingly, toxic
peptides may aid in treating pain [41], neurological and car-
diovascular diseases, diabetes and cancer [32]. A prominent
example is the type 2 diabetes drug Exenatide, a synthetic ver-
sion of a glucagon-like peptide-1 analogue found in the venom
of the Gila monster Heloderma suspectum [7].
As bioactive peptides obtained from natural sources have
been subject to aeons of selective pressure, they show
considerable plusses over artiﬁcially/chemically conceived
peptide-like compounds. Namely, they excel in stability
and target afﬁnity, both of which are extremely chal-
lenging to achieve or reproduce through rational peptide
design, screening of libraries of randomly composed peptides
or peptidomimetics. Although we appreciate the intelli-
gence of peptide medicinal chemists, and other traditional
(bio)chemistry based pharmacologists, we believe that much
is still to be discovered from the natural bioactive peptides
used all over the biological taxonomy (from microorganisms
over plants to animals). With so many of these being used as
drugs by so many different species for so many different pur-
poses, it is clear that mankind can still learn a lot from the
implied biology. We would, therefore, wholeheartedly support
an adjustment of the name of the ‘Natural Peptides to Drugs’
NP2D discussion forum to ‘NP4D’ (Natural Peptides for Drugs).
omics 4 ( 2 0 1 4 ) 58–69
Fig. 1 – Approaches for peptide afﬁnity analysis. Legend:
cyan rods: speciﬁc target binders, light grey rods other
peptides. Dark larger rods in right panel represent
bacterophages. Orange forks represent speciﬁc peptide
targets (e.g. a GPcR). Grey forks represent non-speciﬁc
targets. Peptide afﬁnities towards one or several targets can
be investigated by immobilising either of both and
identifying the binding species (e.g. via detectable tags
and/or via mass spectrometry). A third option is phage
display, where peptides of interest exposed on the surface
of bacteriophages bind to their target. Their respective DNA
sequence is contained within the phage and allows60 e u pa open prote
3.2. Peptidomics
To date, one only begins to grasp the magnitude of peptides
occurring in nature, a considerable share of which poten-
tially offers therapeutic or diagnostic merit. Therefore, more
emphasis at studying the seemingly endless variety of natural
peptides and their bioactivities, is deﬁnitely justiﬁed. This is
exactly what the recent science of ‘Peptidomics’ is all about.
In the past decade, we have seen great technological
strides in peptide manipulation and analytical assessment.
These include advances in liquid handling devices, syn-
thetic protein synthesis, recombinant protein expression,
multispectral micro-plate technologies, mass spectrometry,
liquid chromatography, cell culture methodologies, sequenc-
ing technologies, imaging tools and high throughput peptide
screening protocols [6]. Coupled to these technological
advances, the commercial biotechnology sector is steadily
growing [6], yielding increasednumbers of commercially avail-
able biochemical assays and high throughput screening tools.
Whereas expensive high-tech proteomic techniques have pre-
viously mainly been adopted in big pharma and biotech, we
now see that the newest technologies are becoming accessi-
ble and are being developed primarily in academia and small
biotech. Given themanifold ofmodern tools, a new generation
of modern drug designers is emerging, exploiting the poten-
tial offered by the latest developments in all relevant scientiﬁc
disciplines, such as biology, biochemistry, genetics, transcrip-
tomics, proteo/peptidomics, computer science, mathematics,
and many others.
A systematic approach to identify biologically and phys-
iologically active peptides and thus their pharmacological
promise is fundamental to the study of peptidomics. This
relatively young discipline aims to holistically analyse the
spectrumof peptides found in any chosen organism,mostly by
means of mass spectrometry (MS), tightly linked to advance-
ments in bioinformatics technology which is essential to keep
track of and cope with the huge data sets generated.
Evolution towards high-throughput MS analysis in both
qualitative identiﬁcation and quantiﬁcation was aided by the
latest improvements in ionisation (mainly electrospray, ESI)
and in high speed, high sensitivity and resolution analysers
such as orbitrap systems. In addition, the emergence of mass
spectrometry imaging (MSI) represents one of the most fas-
cinating progresses in this ﬁeld revealing the distribution of
peptides in a biological sample and consequentially inferring
their potential biological source and purpose [40].
3.3. Peptide drug candidate screening
For a conventional drug candidate screening, the so-called
‘lead discovery’ process, in which traditionally large sets of
typically synthetic small molecular compounds of predeﬁned
structure are pharmacologically tested, it is essential to dis-
pose of well-characterised peptide libraries to run a peptide
drug discovery programme. However, also ‘reverse pharma-
cology’ using chromatographically fractionated extracts from
originally impure biological sources of ‘natural’ peptide mix-
tures, is an approach which, thanks to the technological
advances in peptidomics of the past years, may prove to be
much more successful compared to the past.identiﬁcation of the peptide.
Entirely parallel to the high throughput screening of
small molecule chemical libraries, synthetic peptide chem-
ical libraries can be produced using today’s technologies.
These can include natural peptide sequences, supplemented
with derivatives thereof, such as naturally occurring post-
translationally modiﬁed and truncated isoforms, or entirely
artiﬁcial peptides. Indeed, peptides of any deliberately chosen
or randomly assembled sequence can be produced by purely
chemical means or by recombinant organisms. Both allow
for an immense ﬂexibility in sequence and post-translational
modiﬁcations (PTMs) enabling the creation of correspondingly
vast libraries which potentially contain substances of thera-
peutic interest. We remark here that the choice of residues
is by far not limited to proteinogenic amino acids, and is
basically only limited by the imagination and competence
of the synthetic peptide chemist and/or peptide molecular
biologist. Indeed, while chemical synthesis may integrate any
compound able to bondwith the nascent peptide [1], the intro-
duction of artiﬁcially expanded genetic codes has widened
the range of recombinant peptide structures by inserting non-
conventional amino acids [66,52].
Three strategies for screening artiﬁcial peptide libraries can
be distinguished (Fig. 1). In the ﬁrst approach, peptides synthe-
sised on a solid support are cleaved off for activity screening
[26]. Secondly, peptides are assessed while still attached to the
solid phase on which they were synthesised. Finally, phage
display is the third approach where bacteriophages express-
ing the peptide and exposing it on their surface are analysed
for their afﬁnity to a selected target.
Besides the former peptide chemistry- and molecular
biology-based strategies to populate peptide libraries which
can be screened in straightforward pharmacology tests, also
reverse pharmacological approaches starting from natural
sources of biological peptide mixtures have become a very
realistic alternative. Here, screenings are performed with ini-
tially uncharacterised natural peptide structures isolated and
fractionated from their biological source. Biologists help to
mics 4 ( 2 0 1 4 ) 58–69 61
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Fig. 2 – Means of producing therapeutic peptides. Peptide
manufacturing can be achieved entirely through chemical
synthesis, either in the solution phase (top left), coupled to
a solid phase (top right) or by the combination of both.
Alternatively, peptides can be produced by recombinant
microorganisms (bottom left) or by extraction from their
natural (plants or animal) source (bottom right).e u pa open proteo
dentify the sources with the highest potential, considering
he disease target aimed for. Rich mixtures of biological pep-
ides can be found throughout the entire taxonomy, from
ertebrates over invertebrates and plants to microorganisms.
lassical examples are venom and defensive gland secretions
hich are found throughout zoology (see e.g. www.np2d.com;
ww.venomics.eu).
The components of peptide libraries can be assayed for
heir bioactivity in vitro (target afﬁnity, binding kinetics, etc.)
nd in vivo (altered gene expression, cytotoxicity, etc.). Combi-
atorial analysis of known peptide sequences (e.g., Ala-scans)
nd the extent as to how changes in the primary struc-
ure affect the original biological activity, enables to reveal
tructure–function relationships [18]. This ‘deconvolution’
llows the selection of sequences for peptides with a desired
ctivity. As such, it essentially provides the fundament for
ational design of peptides with predeﬁned biological effects.
In all cases, peptide library screenings are intended to
how molecular interaction with a drug target using different
isualisation technologies comprising colorimetry, ﬂuores-
ence microscopy, ﬂow cytometry and others. Classes of
iomolecules which have previously been extensively investi-
ated and successfully modulated as traditional drug targets
nclude ion channels, nuclear or G-protein-coupled receptors,
ranscription factors or enzymes.
. Large-scale peptide production
nce a peptide has been selected for further development as
harmacon, it needs to be produced in large quantities with
onsistent quality, according to good manufacturing practice
GMP) rules.
The strategy for producing a peptide is largely determined
y its size and chemical features. A variety of technologies
uch as chemical synthesis, recombinant DNA technologies,
ell-free expression systems (in vitro translation) and trans-
enic plants or animals have been adopted for this purpose
Fig. 2).
Traditionally, the production of natural compounds is
chieved by using a microbial or fungal strain that underwent
series of induced mutations and subsequent screenings
or productivity. Through this process, the production yield
ay typically be raised by up to three orders of magnitude.
peciﬁcally designed strains with enhanced protein synthe-
is, secretion and folding capability provide a solid platform
nd starting point for reaching high peptide yields [34].
Large-scale operations incorporating chemical synthe-
is as the core production technology may be seen as an
ttractive alternative to existing recombinant DNA-based or
iocatalyst-based methodologies [65]. Chemical synthesis can
e distinguished into three major categories, namely solution
hase, solid phase and hybrid approaches. Selection of the
ost favourable production process primarily depends on the
et objective and the limitations that every method presents.
The majority of peptide pharmaceuticals are produced inigh volumes using solution phase chemistry which is prefer-
bly employed for small to medium-sized peptides. Prolonged
evelopment times are a major drawback for the application
f this technique especially during early clinical studies whenrapid production of the desired substance is crucial. Never-
theless, signiﬁcant advantages of this methodology are the
well-established isolation, characterisation and puriﬁcation
protocols of the intermediate products [1]. On the other hand,
solid phase peptide synthesis (SPPS) has enabled the produc-
tion of large, complex peptides of pharmaceutical grade purity
on a large scale [1,65]. Finally, hybrid processes combining the
advantages of both techniques may offer even greater poten-
tial [1].
Irrespective of the upstream production method of choice,
downstream processing is a vital step in the manufacturing of
peptide pharmaceutical products, since it involves the critical
steps associated with product isolation and puriﬁcation [1].
5. Peptide drug registration
Peptides represent a special case in regulatory affairs, since,
depending on its properties and manufacturing, a peptide is
sometimes regarded as a conventional chemical medicinal
product, and in other cases as a biological entity.
The United States Food and Drug Administration (FDA)
traditionally handles peptides as conventional drugs, not as
biological products [20]. This goes along with the focus of
examination on the drug composition and compound struc-
ture rather than themeans ofmanufacturing. According to the
FDA, the upper size boundary of chemically synthesised pep-
tides is at 100 amino acid residues. Exceptions, however, are
made where peptides otherwise meet the statutory deﬁnition
of a biological product, such as in the case of peptide vaccines.
omic62 e u pa open prote
The European Medicines Agency (EMA) does not provide
such distinction based on size. Instead, peptides are sim-
ply treated as biological entities, if they are either extracted
from their natural sources or recombinantly produced [15,16].
Chemically synthesised peptides, accordingly, are treated as
conventional smallmolecular chemical entities. Nevertheless,
a peptide may be regarded as signiﬁcant therapeutic inno-
vation, as for instance has been the case for Exenatide [17].
This enables the centralised approval procedure for gaining
marketing authorisation in the entire EU at once.
In terms of manufacturing, only one guideline speciﬁ-
cally addresses peptides, i.e. the “Guidance for Industry for
the Submission of Chemistry, Manufacturing, and Controls
Information for Synthetic Peptide Substances” from the FDA’s
Center for Drug Evaluation and Research [19]. It speciﬁes that
the lot release speciﬁcations should be sufﬁcient to ensure the
identity, purity, strength and/or potency of the peptide and to
demonstrate lot-to-lot consistency [58].
A poignant saga illustrating the ‘resistance’ certain pep-
tide compounds face on their way to the drug market, is
this of magainin [42]. Even after completion of phase III, FDA
in 1999 decided against approval of pexiganan (a 22mer lin-
ear peptide analogue of magainin originally identiﬁed from
Xenopus laevis). The reason was that the trial did not show
superior efﬁcacy over other antibiotics used in the indication
under investigation. The fact that magainin, because of its
unique mode of action (polycationic peptide with hydropho-
bic residues forming transmembrane pores in the highly
negatively charged bacterial cell membranes, bleeding the
microbial cell to death), is virtually impossible for a bacterium
to develop resistance against, was not taken into account.
Whereas typically, regulatory issues tend to elongate the dura-
tion of clinical trials by a signiﬁcant amount of time, the
FDA launched the Antibacterial Drug Development Task Force
in September 2012 [21] in order to increase the efﬁciency of
antibiotic development including the clinical trial design. Sim-
ilar developments are on-going in Europe by the EMA; new
guidelines are released which concern the clinical criteria for
evaluating antimicrobials [22,31].
The currently changed attitute towards antimicrobial pep-
tides is illustrated by surotomycin (developed by Cubist
Pharmaceuticals). The compound, a lipopeptide very compa-
rable to vancomycin (a currently available common antibiotic;
[35]), is now in phase III against C. difﬁcile infections and has
been designated ‘qualiﬁed infectious disease product’ (QIDP) sta-
tus under the FDA ‘generating antibiotic incentives now’ (GAIN)
act. This means that priority review, fast-track status, and a
ﬁve year exclusivity after license are applicable [22].
6. Peptide pharmacodynamics and
pharmacokinetics
Many of the challenges peptides face in the drug development
process occur in the preclinical development phases. Preclin-
ical biological activity is evaluated using in vitro and in vivo
pharmacology assays that determine the effects of a product
(pharmacodynamics) related to its clinical activity. Additional
important pharmacological parameters include the phar-
macokinetics (PK, absorption, distribution, metabolism ands 4 ( 2 0 1 4 ) 58–69
excretion; ADME) [38]. Determination of all these parameters
to the full extent is especially challenging in the case of syn-
thetic or recombinant peptides (or proteins), as they usually
show patterns deviating from more traditional small molecule
pharmaceuticals [60] which typically reach their (often intra-)
cellular targets by diffusion into all cells of the body. This
is quite different from the regular bioactive peptide which
exerts its effect through binding with a cell surface receptor,
after having successfully overcome the challenges inherent
to reaching the general circulation (see also below “Peptide
drug formulation”). Here peptides have a slight disadvantage
compared to conventional small molecule drugs, which not
seldom are selected for their easy crossing of cellular mem-
branes/barriers.
Pharmacology studies of peptide drug candidates are still
very tough, as the targeted analytical identiﬁcation and quan-
tiﬁcation of peptide drug substances from complex matrices
is still strongly limited [12]. The actual analytic screening for
peptides in preclinical studies is mainly based on detection
via immunological assays. Although these methodologies do
offer a high throughput, they suffer from major limitations
in terms of speciﬁcity and dynamic range [25]. At the same
time, the development of new protocols and assays is cur-
rently still extensive and laborious [12]. Consequently, in terms
of reliability and economics, analytical techniques suitable
for routine targeted peptide metabolism (‘bioanalysis’) studies
still need to be developed.
A solution to cross this technological chasm may come
from the most recent advancements in peptide mass spec-
trometry (MS), expanding the tool box of MS technologies. The
optimal integration of innovative instrumentations, protocols
and efﬁcient data treatment tools available to date will lead to
dedicated workﬂows to analyse speciﬁc peptides in biological
complex matrices [12].
Aspects like internal (isotopically labelled) standard avail-
ability for the generation of reliable calibration curves,
together with instrumental setup are capital in peptide quan-
tiﬁcation and ADME studies. Moreover, the panorama of data
acquisition is complicated by the diversity of mass spectrum
deconvolution technologies and data mining software. Yet,
several examples exist of how the most recent MS evolutions
can be successfully applied in the context of peptide identiﬁ-
cation and quantiﬁcation from complex biological matrices.
Technologies like selected reaction monitoring (SRM) and
high resolution mass spectrometry (HRMS) actually emerge as
very promising [12], especially in the investigation of peptide
metabolism. These advancements, hand-in-hand with ade-
quate sample preparation workﬂows, including high and ultra
performance liquid chromatography – bioﬂuids such as blood,
cerebrospinal ﬂuid or others comprise very distinct analytic
environments – may help solve this still major bottleneck in
pharmaceutical peptide metabolism studies.
Finally also the above mentioned mass spec imaging (MSI)
technology is very promising as tool to pre-clinically map
the distribution of drugs and their metabolites in the body,
replacing the current autoradiography (MSI does not require a
radiolabel). Whereas MSI is already being successfully used
in small molecular drug PK (see e.g. [48]), it still needs to
be successfully demonstrated for peptide drugs and their
metabolites.
mics 4 ( 2 0 1 4 ) 58–69 63
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Fig. 3 – Modern formulations for the protected and
optionally targeted delivery of therapeutic peptides. Several
modern formulations offer enhanced tissue penetration,
delayed decay of therapeutic peptides and targeted delivery
by exposing speciﬁc receptor ligands. Liposomes (top)
harbour lipophilic peptides within the lipid bilayer, while
hydrophilic peptides are stored in the aqueous core. On the
other hand, micelles (bottom left), nanoemulsions (bottom
centre) and polymer nanoparticles (bottom right)
incorporate lipophilic peptides into their core. The insert at
the top left liposome represents a typical cell membrane
amphiphilic (phospho)lipid with light grey denoting the
polar head group and dark grey indicating the apolare u pa open proteo
. Peptide drug formulation
s promising as peptide drug candidates may be, a number of
onceptual limitations remain associated with the traditional
mage of a peptide as a typical medicine. This perception is
argely substantiated by Lipinski’s “rule of ﬁve” which sum-
arises the ideal pharmacokinetic properties of the most
uccessful (chemical) drug candidates of the original pharma
ndustry. This decree dogmatises that peptides are less likely
opass through the gastrointestinal (GI) tractwall as compared
o small molecules due to their larger size and comparatively
ow solubility [65].
Many challenges peptides experience on their way to
ecoming an effective drug originate in their physicochemical
roperties which together result in a poor oral bioavailabil-
ty. Due to their hydrophilicity, peptides exhibit limited ability
o cross physiological barriers. In addition, peptides are con-
ronted with efﬁcient hepatic and renal clearance. Even once
nside the systemic circulation, peptides typically have rather
hort half-lifes due to aggressive degradation by amultitude of
roteases [3]. These aspects, intrinsic to the chemical nature of
eptides, have compelled cumbersome administration routes
uch as direct injection of repeated doses, which in turn
esulted in low patient compliance [3].
Aside the classic subcutaneous, intramuscular and intra-
enous administration, alternative routes have been devel-
ped, including the mucosal track (nasal spray, pulmonary
elivery or sublingual delivery), the oral route (GI tract pen-
tration enhancers, protease inhibitors or carriers) and the
ransdermal path (patches; [3,65]). For instance, a peptide pill
or oral administration is developed (Enteris Biopharma) the
oating ofwhich effectively protects the active substance from
igestion in the stomach, allowing its release in the duo-
enum. A number of excipients protect the peptide against
eptidases and facilitate its paracellular uptake through the
ntestinal wall into the systemic circulation [57].
Beneﬁts of the pulmonary intake are a very large available
bsorptive and highly permeable surface, extensive vascu-
arisation, with concomitant rapid onset of pharmacological
ction, a more uniform distribution of the drug product and
more sustained drug release which allows a reduction of
he dosing frequency [2,28]. Like other parenteral administra-
ions, the ﬁrst passmetabolism is avoided. Also a 10–200 times
igher bioavailability (higher drug product plasma concentra-
ions) can be achieved because of the smaller volumes used
56,63,2].
Besides alternative delivery systems, various formula-
ions have been devised in the past, trying to deal with the
forementioned physicochemical limitations, to help advance
romising peptide drug leads into pharmaceutical devel-
pment. Again, most of these medicinal preparations are
hemistry- and nanophysics-based. Indeed, chemical incor-
oration of sugars like trehalose, sucrose, maltose, glucose,
f salts like potassium phosphate, sodium citrate, ammo-
ium sulphate and/or of other agents such as heparin into
he prospective formulations have been found to increase
he solubility and in vivo stability of peptides. Employment of
ationic andanionic surfactants suchas cetrimide and sodium
odecyl sulfate (SDS) have shown enhanced transportationmoieties.
of peptides across bodily membranes. Considerable increase
in resistance against proteolysis is often achieved through
co-administration of protease inhibitors such as sodium gly-
cocholate, camostat mesilate or bacitracin. Moreover, the
attachment of polymeric molecules such as polyethylene
glycol (PEG) and polyvinylpyrrolidone (PVP) and even the
encapsulation of the peptide into nanocarriers are employed
for extended bioavailability (Antosova, Mackova et al., 2009).
Nanocarrier technology indeed seems a promising inno-
vation to increase peptide pharmacodistribution through, for
example, nanoparticles, liposomes and micelles (Fig. 3). These
are thought to effectively create a closed carrier that pro-
tects the active compound from destabilising external threats
such a peptidases. In combinationwith pulmonary inhalation,
nanocarriers have the beneﬁt of prolonged drug release due
to the combination of peptide protection by the carrier’s shell
with carrier accumulation [2].
In general, an ideal nanocarrier should be composed of
inert and biodegradable material and be able to efﬁciently
encapsulate andprotect the peptide against degradationwhile
at the same time maintaining proper drug product target-
ing [28]. Compositions of polymeric formulations can be used
to tune the biological behaviour of nanocarriers by modu-
lating compound properties such as mucoadhesiveness [8].
An example is the cationic polysaccharide chitosan, the ionic
interactions of which with the negatively charged sialic acid
groups in mucin provide exceptional binding. In combination
omics 4 ( 2 0 1 4 ) 58–69
Fig. 4 – Graphical representation of number of peptides in64 e u pa open prote
with its ability to open tight junctions, chitosan effectively
favours the utilisation of the paracellular pathway [11,53,2].
Hybrids can be created by combining chitosan with other
polysaccharides or oligosaccharides in an attempt to further
improve the physical properties and pharmacological perfor-
mance of peptide drug formulations [23,28].
Other synthetic polymers such as polylactic acid (PLA)
and poly(lactic-co-glycolic) acid (PLGA) have been found
viable substitutes. Their consistency in terms of peptide drug
product release in combination with good biodegradability
guarantees optimal safety. Accordingly, the FDA has already
approved a number of respective marketed products and clin-
ical applications [11,2,28].
Liposomal nanocarriers are composed of one or multiple
phospholipid bilayers. Speciﬁc ligands conjugated with mod-
iﬁed PEG molecules in the shell offer targeted delivery [30,28].
However, liposomes often face varying instabilities in biolog-
ical ﬂuids [2]. Nanoparticles which consist of a solid (both at
ambient and body temperature) lipid matrix dispersed in an
aqueous phase may offer an alternative. One distinguishes
solid lipid nanoparticles (SLNs) and nanostructured lipid car-
riers (NLCs). While SLCs are rigidly structured, NLCs consist
of both solid and liquid lipids allowing for an increased load-
ing capacity [39,43,2]. Finally, self-nanoemulsifying systems,
i.e. isotropic mixtures of oil and surfactant forming thermo-
dynamically stable oil-in-water emulsions,mayhavepotential
for enhanced oral bioavailability of poorly water soluble pep-
tides [28].
Besides these modern (nano)technology-inspired formula-
tions, we here would like to draw the attention to the wide
variety of bioactive peptide delivery systems found in nature.
Evolutionhas designeddirect injection devices, verymuch like
injection needles, such as fangs or venom teeth in various rep-
tiles, harpoon-like radulas in snails, or claws. However also
organisms lacking these appear to successfully use bioactive
peptides in their gland secretions. A careful analysis of the
composition of peptide-containing venom and defense glands
in animals like amphibians, may, therefore, give hints as to
howpotential therapeutic peptides can be successfully formu-
lated. The exosomal release which is observed from various
venom glands in a way is comparable to the micellar encap-
sulation of peptides described above. Biology also hints to
additional tricks to ensure effective use of peptide bioactives.
In nature peptides are almost never secreted on their own,
but always in cocktails, basically a mixture of three types of
peptides. These not seldom contain polycationic amphipatic
(poly)peptides (sometimes catalogued as ‘antimicrobial pep-
tides’ (AMPs)) which could serve as membrane penetrating
delivery systems. Co-secretion of ‘peptidase inhibitors’ is also
a strategy seen in various animal defense glands. Finally
various (often post-translational) modiﬁcations on the true
‘bioactive peptides’ ﬁt in a strategy to render the (active
part of the molecule) improved/prolonged stability as well as
tighter receptor binding. These include sequence elongation
protecting the bioactive site from rapid exoprotease diges-
tion, C-terminal amidation and/or N-terminal ring formation
(pyroglutamic acid from glutamine) for charge suppression
(reduction of hydrophilicity), disulﬁde bridge formation for
increased structure preservation and rigidity, and isomeri-
sation of selected peptide terminal residues (from l- intopreclinical and clinical development as of 2013 [31].
d-amino acid) for enhanced exopeptidase resistance. Exam-
ples can be found in the defensive secretions of Phyllomedusa
burmeisteri and Bombina variegata, as described elsewhere in
this special issue [47].
8. Clinical development
The therapeutic peptide development is growing. In 2011
alone, there were between 500 and 600 peptides in pre-clinical
phases (Fig. 4; [31]). The year 2012 has proven to be another
milestone for the peptide pharmaceutical sector, with 5 and 6
peptides meeting market approval respectively in Europe and
in the USA. This was the highest number of approvals ever
achieved for new biological entities (NBEs) in one year [29]
which renders some optimism to the sector. This optimism is
conﬁrmed by the statistics, as the regulatory approval rate for
peptides is around 20%, versus 10% for small molecules [31].
In addition, the number of peptides per year entering clinical
trials has steadily increased from 1 in 1970 to currently around
20 [31].
As of April 2012, the clinical pipeline for peptide drugs was
composed of 128 peptide candidates. These included 40 in
phase I, 74 in phase II and 14 in phase III (Fig. 4). The robust-
ness of this pipeline is largely due to the notable expansion
in the ﬁeld of peptide therapeutics during the late 1990s and
2000s, ultimately leading to the number of approvals observed
in 2012. Considering the general failure rate of the clinical
pipeline [29], these numbers prove very promising.
In Phase I, the most represented indications are pain (more
than 30%), cancer and cardiovascular diseases. In Phase II and
III, in which cancer is the leading target (accounting for more
than 15% and 40%, respectively), one ﬁnds, next to pain and
infectious diseases, also indications not much represented in
the current market, such as dermatology, allergies, and CNS
disorders [29].
8.1. Typical (GPC) receptor binding peptides
One area of research that has shown promising develop-
ment are the use of peptide therapeutics in treating type
2 diabetes (targeting the glucagon-like peptide 1 receptor).
Already three peptides have received approval in 2012, with
14 working their way through the pipeline. A most excit-
ing aspect of these peptide drug candidates is the variety in
drug formulation of molecular formats (with peptides being
covalently linked to small molecules, carbohydrates, lipids,
biopolymers, polyethylene glycol or proteins (see above)) and
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heir mechanisms of actions (including speciﬁc cell-targeting
eptides and cell-penetrating peptides) currently being elu-
idated. Thus, substantial efforts are being made to modify
olecular properties of peptide drug leads to improve their
unctionality. For example, half-life extension was the ratio-
ale for four peptides (CBX129801, CVX060, LAPSExd4, PB1023)
n phase II, whereby peptide conjugation to polyethylene or
gG substantially increased peptide stability in circulation
rom minutes to days or even weeks. Improved biological bar-
ier crossing/cell-penetration was the rationale behind the
esign of three other peptides (CBP501, AM111, ACT1) also in
hase II. Typical amphipathic and cationic features of these
eptides are enhanced by the molecular addition of cell-
enetration promoting sequences such as the transcription
ransactivation (TAT) sequence from the HIV virus [36].
.2. Antimicrobial peptides
ith the frightening advent of global increase of micro-
ial resistance to conventional antibiotics, the search for
lternatives has become of utmost importance, and the indus-
ry as well as the regulatory authorities are realising the
otential of antimicrobial peptides (see also above).
A recent overview of antimicrobial peptides currently in
linical phases by [22], includes 10 compounds (developed in
0 different companies both in North America and in Europe).
n this list we see Pexiganan (magainin, see above) reappear,
lbeit no longer developed by the original company Magainin
harmaceuticals, but byGenaera, the name the enterprisewas
e-baptised in.
.3. Peptides as vaccines
n entirely different sort of therapeutic peptides are the
eptide vaccines. These peptides, representing inactive,
on-virulent fragments of pathogen proteins are becoming
radually more mainstream. On-going trials are spanning all
hases of clinical development. The list of beneﬁts for espe-
ially synthetic peptides as vaccines includes their ease of
uality control, chemical stability and the absence of onco-
enic, toxic or infectious material [51]. Whereas not many
uccesses have recently been achieved by employing peptide
accines [44], the advent of personalised peptide vaccination
PPV) could herald changing times. Taking factors into account
uch as the human leucocyte antigen (HLA) system and pre-
xisting host immunity [44], PPV may have a future, providing
urrent phase III trials are as successful as they promise to be
44,67].
.4. Future perspective
ome very promising peptides to watch out for in the coming
ears are now in late phase clinical trials. About half of
hem are intended for oncology, metabolic or cardiovascu-
ar treatment as well as for remedying infectious diseases
31]. Especially for illnesses requiring prolonged therapy,
eptides have a competitive advantage over conventional
mall molecule drugs. In terms of general safety, peptides
ave a comparatively small toxicological footprint. Due to
heir extremely high speciﬁcity for their intended target (the4 ( 2 0 1 4 ) 58–69 65
peptide receptor), in combination with the fact that they are
extracellularly active (not requiring systemic diffusion and
hence extreme dilution over all cells), much lower amounts
can be formulated. Moreover after peptide receptor binding
and signal triggering, highly efﬁcient peptide catabolism
through proteolytic degradation yields simple amino acids,
which are recycled in the body in everyday metabolism such
as protein synthesis. Compared with other small molecular
chemical entities, which often represent extreme challenges
to the body’s detoxiﬁcation mechanisms, peptides suffer from
little if any accumulation in the body, nor in the environment.
In contrast to various poorly metabolising or absorbing small
chemical drugs, no surface water pollution occurs by residual
active substance excretion into the environment after peptide
drug use.
It can be concluded that the pharmaceutical peptide
pipeline is strong and stable, with several candidates
approaching drug approval status. The commercial value of
the therapeutic peptide market is well established (see below).
However, the recent and nascent approvals promise to sub-
stantially increase the market value of peptide therapeutics
in the coming years, in the areas of diabetes, oncology [29,31]
and beyond.
9. Peptide patents
Several sources report that the number of patent applications
involving peptide-related technology has signiﬁcantly grown
in the last decades. A recent update on patent applications is
available [46].
An illustrative example of a patent application involving
peptides with pharmaceutical potential is provided by the
approved patent EP1590458B1 “Bradykinin B2 Receptor Antag-
onist Peptide from Amphibian Skin” [54]. The patent discloses
the sequence of a peptide (kinestatin) isolated from toad
(Bombina maxima) defensive skin secretion, while claiming the
protection for kinestatin analogues, prodrugs including the
peptides, fusion peptides and multimeric peptides. At the
same time, it gives a broad indication of the potential thera-
peutic application areas, including cardiovascular disorders,
inﬂammation, asthma, allergic rhinitis, pain, angiogenesis
and the like, glaucoma, hydrocephalus, spinal cord trauma,
spinal cord oedema, neurodegenerative diseases, including
Alzheimer’s disease. The claims comprise the application of
the patented molecules wherein said peptides are present in
or conjugated onto a liposome or microparticle that is of a
suitable size for intravenous administration, but that lodges
in capillary beds, thus opening the road to overcoming poten-
tial administration hurdles. This patent application provides
the reader with a general framework for patent application
involving peptides, namely disclosure of the main amino acid
sequence motif, examples of analogues, prodrug derivatives
and a broad deﬁnition of therapeutic areas.
Within the Cooperative Patent Classiﬁcation (European
Patent Ofﬁce, 2013), category A61K38 includes “Medicinal
preparations contain peptides” as a subdivision of category
“Preparations for medical, dental, or toilet purposes” A61K.
This is not to be confused with category C07K “Peptides” that
is including application of peptides within several ﬁelds, such
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Fig. 5 – Trend in patent applications for therapeutic
Fig. 6 – Worldwide peptide drug market distribution in
2011. Global peptides net sales amount to USD 14.7 billion
(the relatively minor contribution of Octreotide to the
generics market (USD 0.15 billion) was not considered).peptides from 1980 until 2012 [14].
as food. An Espacenet database query for patent applications
belonging to category A61K38 for each year between 1980 and
2013 (the data for the partial year 2013 were extrapolated to
the whole year) yields an interesting graph (Fig. 5; [14]).
Approximately 389,320 patent applications within the pep-
tide ﬁelds have been published in the interval 1980–2013.
Starting from the year 1996 the number of patent applica-
tions per year have invariably surmounted 10,000, a very high
number, reﬂecting a very dynamic development of the pep-
tide market. At the same time, it also shows an apparent peak
in the number of applications per year reached in 2003 (with
23,690 new peptide-related patent applications).
Considering that an average approval time for new drugs
is 10 years and that the peak in peptide patent applications
occurred in the interval 2000–2005, one may predict a peak
in the number of peptides entering the market as new drugs
between 2010 and 2015. Apparently, an unprecedented num-
ber of peptides have in fact received market approval in the
years 2010–2013 (see above). Considering that a typical pro-
tection time for a granted patent is 20 years, and that an
off-patent drug tends to lose a signiﬁcant part of its sales rev-
enue to price-based competition by generics in the few years
after the end of patent protection, we anticipate that peptide-
based drugs may deliver rising sales revenues for pharma in a
signiﬁcant numbers of years to come, reasonably beyond 2020.
10. The peptide pharma market
To date, around 100 therapeutic peptides (mostly innovative
synthetic ones) are on the market in the USA, Europe and
Japan, including those for diagnostics applications [29]. The
increasing numbers of recently approved peptides is a result
of the well-ﬁlled pipeline, as described above. The market
appears dominated by the three peptides Goserelin/Zoladex
and Leuprolide (two gonadotropin releasing hormone ago-
nists, used in hormone-sensitive breast and prostate cancer),
and Octreotide (a somatostatin mimic used against various
tumours), which account for annual sales (2011) between USD
1.2 and 1.4 billion [45,4,59], in total around 25% of the global
peptide market [62].A clear trend over the past years is the continually expand-
ing contribution of peptides to the worldwide pharmaceutical
market. Of a global market worth USD 956 billion in 2011 [27],
the peptides’ share was about USD 14.4 billion [29,62], com-
prising around 1.5%. The major contributor is the US market,
which accounts for 40% of the global peptide sales. In 2011, the
cancer sub-market was the largest, representing 21% of the
total peptide market, followed by metabolic disorders, gastro-
intestinal diseases and respiratory indications [62] with 86%
of the approved peptide drugs working through the parenteral
route. As indicated above, however, alternative routes are fore-
seen to expand [29]. The totalmarket potential of peptidesmay
be signiﬁcantly larger, since, in addition to the therapeutic
pharmaceutical market, peptides are expected to contribute
more and more in other markets such as the nutraceutical
business [5].
In the current stagnating pharmaceutical industry, pep-
tides are considered to have added value, by representing
a potential solution to more efﬁcacious disease treatment.
Already today they appear mature compounds addressing
unmet medical needs, and accelerating the personalised
medicinemodel [10]. In addition, peptides promise to combine
the lower production costs of conventional (small molecular
chemical) drugs with the high speciﬁcity of (the larger) biolog-
ical entities.
Importantly, the proportion of peptides in pharma is antic-
ipated to increase, since it is estimated to grow faster (9.4%
annual growth in 2012–2018) [62] than the global industry
(3–6% annual growth in 2012–2016) [27]. Not only is the num-
ber of approved peptide drugs expected to grow but also the
diversity of treated indications.
It is remarkable that generic sales already account for a
considerable portion of the peptides’ market. In 2011, gener-
ics represented 35% of the peptide market, with three of the
ﬁve top selling peptides being generics [5,62]. Octreotide for
instance has a generic version accounting for USD 0.15 bil-
lion annual sales [9]. In comparison, generic sales in the global
pharmaceutical market account for around 21% and biosimi-
lars in the biologics sub-market for around 0.4% in the same
year [27].
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Summarising, the peptide market today, although still
epending on a few blockbusters and mature drugs as obvious
rom the contribution of generics to the global sales (Fig. 6),
s predictably increasing. The imminent pipelines indicate a
right future for peptide pharmaca, with numerous innova-
ive peptides on the verge of approval. This endorses peptides
s ﬁrm candidates to contribute to the growth and innovation
f the future pharmaceutical industry.
1. Conclusion
herapeutic peptides have spent decades as niche prod-
cts, while the pharmaceutical industry focussed on small
olecules as medicinal agents. Given the increasing chal-
engeswith the latter compounds, drug developers are turning
ack to the small amino acid chains. Whereas peptides have
een deemed unsuitable for a long time, modern formulations
nd peptide drug desings have achieved to circumvent their
eaknesses to clearly reveal more than a few advantages of
hese molecules. For example, the original need for inject-
ng peptides like insulin is fading, with progressively more
atient-friendly administrations being developed. Addition-
lly, today’s society which critically judges the undesirable
ide effects as well as environmental impact of candidate
edicines should embrace the safety provided by peptides.
Whereas, therapeutic peptides originally were developed
o replace their endogenous lack, the spectrum of avail-
ble candidate peptide drugs is by far not limited to the
uman peptide pool. Indeed, through the modern tools of
eptidomics, bioactive peptides from multifarious organisms
re being discovered. Nature certainly still harbours a vir-
ually inﬁnite array of potential peptidic medications that
wait (human) pharmacological characterisation. At the same
ime, the methods of peptide synthesis have evolved to per-
it highly efﬁcient production of remarkably long and heavily
odiﬁed compounds.
In the light of these advances, the recent rise of peptide
rugs is not a surprise at all. At ﬁrst glance, the decline in ther-
peutic peptide patent applications after a prior peak about
0 years ago may seem discouraging, but this does not nec-
ssarily mean that the market is reﬂecting this trend. On the
ontrary, a largenumber of clinical trials of peptide drug candi-
ates is conducted to date and the market is growing steadily.
iven these premises, we anticipate a bright future for thera-
eutic (as well as diagnostic) peptides.
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